Rezular Fails in Clinical Trials

A new drug for gastrointestinal conditions, called Rezular, did not pass Phase III clinical trials conducted by its Irish developer, AGI Therapeutics. There was no significant difference in patients taking Rezular versus those taking a placebo. The drug did help alleviate certain symptoms, however, and it may be repurposed as a treatment for diarrhea. AGI Therapeutics stock fell considerably with the failed trial. Morningstar.com, May 15, 2009 
2009-06-07 18:47:22